Managed Healthcare Executive10d
CS1, an HDAC Inhibitor, Appears to Reverse Remodeling in PAH
The drug’s developer, Cereno Scientific, believes its oral therapy could have a major impact on the pulmonary arterial ...
Sickle Cell Disease News13d
Bone marrow transplant in teen years may lower stroke risk in SCD
Undergoing a bone marrow transplant during adolescence, but not in adulthood, may lower the risk of stroke with SCD, a mouse ...
Hosted on MSN1mon
Novel PET approach identifies early signs of pulmonary arterial hypertension
A new molecular imaging technique— 18 F-FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early ...
Medscape20d
The Emergence of New Therapeutic Targets in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a vascular remodeling disease that pathologically increases pulmonary vascular resistance. Ultimately, this leads to right ventricular failure and ...
Managed Healthcare Executive13d
PET Imaging Could Help Track PAH Onset, Therapy Response, Study Finds
New research could pave the way toward a new method of pulmonary arterial hypertension diagnosis and monitoring.
Medscape26d
Role of the Serotonin Transporter in Pulmonary Arterial Hypertension
Serotonin can promote both pulmonary vasoconstriction and pulmonary vascular remodeling and is thought to be involved in the pathobiology of PAH. A polymorphism in the serotonin transporter (SERT ...